Risk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis

@article{Alqudah2018RiskOP,
  title={Risk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis},
  author={Abdelrahim Alqudah and Mark McKinley and Ross McNally and U. M. Graham and Chris J. Watson and Timothy J. Lyons and Lana McClements},
  journal={Diabetic Medicine},
  year={2018},
  volume={35},
  pages={160 - 172}
}
AIMS To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy. [] Key MethodMETHODS A search was conducted of the Medline, EMBASE, Web of Science and Scopus databases. Both randomized controlled trials and prospective observational cohort studies of metformin treatment vs. placebo/control or insulin either prior to or during pregnancy were selected.

Real‐world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register

In Australia's Northern Territory, Indigenous mothers account for 33% of births and have high rates of hyperglycemia in pregnancy, and the use of metformin is common.

Prevention of preeclampsia.

Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis

Metformin for any indication during pregnancy is associated with lower GWG and a modest reduced risk of pre-eclampsia, but increased gastrointestinal side-effects compared to other treatments.

Metformin for the prevention of hypertensive disorders of pregnancy in women with gestational diabetes and obesity: a systematic review and meta-analysis

Whether metformin use is associated with the incidence of hypertensive disorders of pregnancy (HDP) is determined and a Bayesian random-effects meta-regression was used to synthesize the evidence.

Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome

The existing evidence around metformin use is summarized both during the preconceptual period and during pregnancy, in relation to reproductive outcomes, and the evidence remains equivocal regarding its efficacy both in optimizing fertility and pregnancy outcomes.

Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial

This trial suggests that extended release metformin can prolong gestation in women with preterm pre-eclampsia, although further trials are needed.

Biochemical Dysregulation of Pre-Eclampsia and Gestational Diabetes Mellitus

  • M. PortelliB. Baron
  • Biology, Medicine
    Prediction of Maternal and Fetal Syndrome of Preeclampsia
  • 2019
The altered physiological parameters, dysregulation of potential protein biomarkers and DNA-related changes (mutations, methylations, miRNAs) will be combined in this review to explore possible underlying mechanisms of pre-eclampsia and gestational diabetes mellitus.

Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.

Metformin exposure was associated with a decreased risk of composite hypertensive disorders of pregnancy in patients with pregestational type 2 diabetes, and data suggest that there may be benefit to metformin administration beyond glycemic control in this patient population.

Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study

PCOS was associated with increased risks of adverse pregnancy and perinatal outcomes and childhood obesity and metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS.
...

References

SHOWING 1-10 OF 61 REFERENCES

Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes

There are no contemporary cohorts examining pregnancy outcomes in women with type 2 diabetes (T2D) in Australia and the chances of complications during pregnancy are low.

Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study

The use of metformin in the treatment of gestational diabetes should be considered, according to a prospective randomised study carried out in Finland.

Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin

We compared metformin with insulin as treatment of gestational diabetes mellitus (GDM). Furthermore, we aimed to characterize metformin‐treated patients needing additional insulin to achieve

Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study

  • S. KhattabI. Mohsen M. Youssef
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2011
Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women.

First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis.

There is currently no evidence that metformin is associated with an increased risk of major birth defects in women affected by PCOS and treated during the first trimester, but larger ad hoc studies are warranted in order to definitely confirm the safety and efficacy of this drug in pregnancy.

Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort

The ability to predict pre-eclampsia in healthy nulliparous women using clinical phenotype is modest and requires external validation in other populations.

Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.

Metformin treatment from first trimester to delivery did not reduce pregnancy complications in PCOS and women in the metformin group gained less weight during pregnancy compared with those in the placebo group.

Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia.

  • YogevChen Rogers
  • Medicine
    American journal of obstetrics and gynecology
  • 2010

Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study.

Maternal androgen levels were unaffected by metformin treatment in pregnant women with PCOS, and met formin treatment of pregnant PCOS women may reduce complications during pregnancy and in the post-partum period.
...